Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BLU-701 |
| Synonyms | |
| Therapy Description |
BLU-701 is a reversible EGFR inhibitor that blocks the activity of mutant forms of EGFR, including C797S, while sparing wild-type EGFR, which results in reduced downstream signaling and potentially leads to decreased tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1262). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BLU-701 | BLU701|BLU 701 | EGFR Inhibitor 4th gen 19 | BLU-701 is a reversible EGFR inhibitor that blocks the activity of mutant forms of EGFR, including C797S, while sparing wild-type EGFR, which results in reduced downstream signaling and potentially leads to decreased tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1262). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05153408 | Phase Ib/II | BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Terminated | USA | 0 |